进展期胃癌术后CIK细胞联合化疗的临床疗效评价

Evaluation of the clinical efficacy of CIK cell combined with chemptherapy for advanced gastric cancer after operation

目的评价CIK细胞联合化疗用于进展期胃癌术后治疗的临床疗效及安全性。方法选择进展期胃癌患者76例,分为CIK细胞与化疗联合治疗组和单纯化疗组,观察血培养和输注过程患者的临床情况以评价CIK细胞输注的安全性,流式细胞分析检测体内T细胞亚群,比较临床近期疗效,用Log-rank检验比较两组无瘤生存期、总生存期。结果自体CIK细胞治疗过程中个别病例主要出现低热、恶心、呕吐等症状,未见明显毒不良反应;CIK细胞输注后CD4+/CD8+比值增高,NK表达比率增高(P<0.05);近期临床疗效,CIK与化疗联合治疗组客观有效率和疾病控制率均高于单纯化疗组(41.03%vs 18.92%,61.54%vs 56.76%),(P<0.05);单纯化疗组术后中位无瘤生存期低于联合治疗组(P<0.05);单纯化疗组术后总中位生存期为36个月,联合治疗组为39个月。结论 CIK细胞与化疗联合治疗是进展期胃癌术后的有效治疗手段,可使机体免疫功能得到改善,近期疗效明显,并且可延长患者无瘤生存期。

Objective To evaluate the clinical efficacy and secruity of CIK cell combined with chemotherapy for adanced gastric cancer after operation.Methods 76 patients who suffered from adanced gastric cancer,were divide into CIK cell combined with chemotherapy treatment group and the chemotherapy group.Blood culture and infusion processe were observed for evaluating security of CIK cell infusion,T lymphocyte subsets in vivo were aralysed with FCM,to compare its short-term clinical curative effect and their cancer-free survival time and overall survival time between the two groups with Log-rank inspection.Results In the process of autologous CIK cell treatment,some cases appeared the symtoms of slight fever,nausea,vomiting,not evident adverse reactions were seen.CD4＋/CD8＋ ratio increased after CIK cell infusion,NK expression increased（P0.05）.In terms of short-term clinical curative effect,the objective effective ratio and the disease control ratio in combined treatment group and CIK were hither than those in the pure chemotherapy group（41.03% vs 18.92%,61.54% vs 56.76%）（P0.05）.The survival time of median cancer-free patients in chemotherapy group after operation was shorter than those of the union therapy group（P0.05）.Patient＇s postoperation median survival time was 36 months in chemotherapy group.Patients in combined treatment group was 39 months.Conclusion The technique of CIK cell combined with chemotherapy is effective,it can improve patient＇s immunity,make the patient＇s cancer-free survival time longer.